Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis

Addition of valsartan therapy to usual care in this model analysis resulted in net cost savings among hypothetical heart-failure patients not receiving ACE inhibitors. Substantial cost savings were realized, regardless of variation in model parameters.